Decision brings precision medicine in psoriasis to all 50 states Vista, CA, April 22, 2026 (GLOBE NEWSWIRE) — Mindera Health, a leader in precision medicine for dermatological conditions, today announced it has received approval from the New York State Department of Health for its Mind.Px test. Mind.Px is a genomic test that utilizes the proprietary

Researchers at UC San Diego School of Medicine have begun a pilot clinical trial to test the efficacy of using ultrasound to stimulate the spleen and reduce COVID-19-related inflammation, decreasing the length of hospital stays.

According to a recent LinkedIn post from Cooler Heads, the company is highlighting a patient experience using its Amma scalp cooling device during chemotherapy. The…

Cooler Heads has made significant strides in cancer care by securing Medicaid coverage for scalp cooling therapies in New York, improving patient access.

New York Medicaid now funds a vital therapy to prevent chemo-induced hair loss, breaking down financial barriers for low-income cancer patients.

The U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA) to the  LimiFlex Dynamic Sagittal Tether , a motion-preserving system for the treatment of lumbar spinal stenosis associated with Grade I degenerative spondylolisthesis following decompression.

Vista, CA, March 18, 2026 (GLOBE NEWSWIRE) — Mindera Health, a leader in precision medicine for dermatological conditions, and Mountaineer Biosciences today announced the launch of Subtilitas, a precision translational medicine platform designed to bring objective, molecular-level insights into dermatology and immunology clinical research Subtilitas integrates non-invasive skin sampling, advanced molecular profiling, and artificial intelligence/machine

CEO Andy Doraiswamy highlights the company’s growth and commercial momentum for its portfolio—including Dayspring®

First-in-Class Non-Invasive Ventilator Weaning Technology Fully Enrolled in Global Randomized Controlled Trial; Public Results Presentation Planned for late 2026 CRESTWOOD, KY, March 3, 2026 — Liberate Medical, a clinical-stage medical device company developing breakthrough neuromuscular electric

NPCD endorsed by the American Venous Forum and the American Venous and Lymphatic Society as an effective option for lymphedema management.

Koya CEO Andy Doraiswamy will highlight the company’s growth and commercial momentum for its portfolio—including Dayspring®.